CA2932266A1 - Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies - Google Patents

Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies Download PDF

Info

Publication number
CA2932266A1
CA2932266A1 CA2932266A CA2932266A CA2932266A1 CA 2932266 A1 CA2932266 A1 CA 2932266A1 CA 2932266 A CA2932266 A CA 2932266A CA 2932266 A CA2932266 A CA 2932266A CA 2932266 A1 CA2932266 A1 CA 2932266A1
Authority
CA
Canada
Prior art keywords
genes
dlbcl
patient
biological sample
lenalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2932266A
Other languages
English (en)
French (fr)
Inventor
Matthew William Burnell Trotter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA2932266A1 publication Critical patent/CA2932266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2932266A 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies Abandoned CA2932266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
US61/913,046 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
CA2932266A1 true CA2932266A1 (en) 2015-06-11

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932266A Abandoned CA2932266A1 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies

Country Status (12)

Country Link
US (1) US20160312292A1 (enExample)
EP (1) EP3077547A4 (enExample)
JP (1) JP2017503481A (enExample)
KR (1) KR20160090390A (enExample)
AU (1) AU2014360316A1 (enExample)
BR (1) BR112016012792A2 (enExample)
CA (1) CA2932266A1 (enExample)
EA (1) EA201691143A1 (enExample)
IL (1) IL245936A0 (enExample)
MX (1) MX2016007179A (enExample)
PH (1) PH12016501023A1 (enExample)
WO (1) WO2015085160A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
WO2016060557A1 (en) * 2014-10-17 2016-04-21 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
EP3347717A4 (en) 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US20200270703A1 (en) * 2017-09-29 2020-08-27 Kyushu University, National University Corporation Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients
MX2022004688A (es) * 2019-10-21 2022-05-10 Celgene Corp Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona.
WO2024258819A1 (en) * 2023-06-15 2024-12-19 The Broad Institute, Inc. Neoplastic cytotoxicity induced by glycosylation
FR3158744A1 (fr) * 2024-01-30 2025-08-01 Universite Grenoble Alpes Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
EP2544687A1 (en) * 2010-03-12 2013-01-16 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
MX353482B (es) * 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.

Also Published As

Publication number Publication date
WO2015085160A3 (en) 2015-07-30
WO2015085160A2 (en) 2015-06-11
BR112016012792A2 (pt) 2017-08-08
US20160312292A1 (en) 2016-10-27
AU2014360316A1 (en) 2016-06-16
EP3077547A2 (en) 2016-10-12
EP3077547A4 (en) 2017-11-08
KR20160090390A (ko) 2016-07-29
PH12016501023A1 (en) 2016-07-04
MX2016007179A (es) 2016-09-08
IL245936A0 (en) 2016-07-31
EA201691143A1 (ru) 2016-11-30
JP2017503481A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
US20160312292A1 (en) Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies
US9365640B2 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3077548B1 (en) Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US20210102257A1 (en) Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor to responsiveness to drugs
EP2412825A1 (en) Leukemia stem cell markers
Lee et al. Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective
US20180238886A1 (en) Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
WO2021087044A1 (en) Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
EP4010022A1 (en) Compositions and methods for diagnosis and treatment of bladder cancer
US12400737B2 (en) Methods of classifying diffuse large B-cell lymphoma
US12559559B2 (en) Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia
Han et al. Changed expression and function of P-gp in peripheral blood CD56+ cells predicting chemoresistance in non-Hodgkin lymphoma patients
WO2021081498A1 (en) Compositions and methods for detecting and treating esophageal cancer
Lee et al. WJSC
Watanabe WJG
Kiewe et al. The combined status of ATM and p53 links tumor development and therapeutic response
NZ617142B2 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191205